Skip to main content
. 2008 Sep 26;466(12):3093–3100. doi: 10.1007/s11999-008-0529-4

Table 1.

Summary data*

Patient demographics, treatment, and outcomes All patients Planned Unplanned p Value
Number of patients 203 139 (68%) 64 (32%)
Age (years) 56 (range, 10–90) 57 (range, 10–90) 53 (range, 22–87) 0.16
Gender 0.38
    Male 113 (56%) 74 (53%) 39 (61%)
    Female 90 (44%) 65 (47%) 25 (39%)
American Joint Committee on Cancer stage
    II 77 (38%) 45 (32%) 32 (50%)
    III 102 (50%) 75 (54%) 27 (42%)
    IV 24 (12%) 19 (14%) 5 (8%) 0.33
Size (cm) 10.7 (SD, 7.2) 11.6 (SD, 7.7) 8.9 (SD, 5.4) 0.02
Duration of symptoms (months) 5 (range, 0.5–132) 5 (range, 0.5–132) 6 (range, 1–120) 0.42
Depth < 0.0001
    Subcutaneous 78 (38%) 35 (25%) 43 (67%)
    Deep 125 (62%) 104 (75%) 21 (33%)
Resection margins
    Positive 6 (3%) 2 (1%) 4 (6%) 0.08
    Negative (< 1 cm) 106 (52%) 86 (62%) 20(31%) 0.08
    Negative (≥ 1 cm) 91 (45%) 51 (37%) 40 (63%)  < 0.0001
Radiotherapy 122 (60%) 81 (58%) 41 (64%) 0.53
Chemotherapy 107 (53%) 83 (60%) 24 (38%) 0.003
Disease at reexcision NA NA NA
    Positive 40 (63%)
    Negative 18 (28%)
    Gross 6 (9%)
Amputation 37 (18%) 29 (21%) 8 (13%) 0.22
Flap and/or STSG for limb salvage procedures 22 (13%) 5 (5%) 17 (30%) < 0.0001
Local Recurrence 31 (15%) 9 (6%) 22 (34%) < 0.0001
Time to local recurrence (months) 22 (range, 3–175) 31 (range, 11–175) 17 (range, 3–117) 0.12
Postoperative followup (months) 58 (range, 24–212) 63 (range, 24–212) 48 (range, 24–132) 0.04
Disease-specific survival
    Alive, NED 107 (53%) 66 (47%) 41 (64%) 0.07
    AWD 11 (5%) 6 (4%) 5 (8%)
    DOD 71 (35%) 54 (39%) 17 (27%)
    DOC 14 (7%) 13 (9%) 1 (2%)

* Data provided as mean (SD), median (range), or number (percentage), as appropriate; significant difference between cohorts; STSG = split-thickness skin graft; NED = no evidence of disease; AWD = alive with disease; DOD = died of disease; DOC = died of other causes; SD = standard deviation; NA = not applicable.